SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (644)4/15/1997 5:44:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Miljenko, Idec has disclosed public info on a new manufacturing facility that Smithkline has started to construct of which Idec has stated that the lead product of this new manufacturing facility is CE9.1. This was confirmed to me again as well as publicly been discussed in previous Idec meetings and presentations. Currently Smithkline is supplying CE9.1 for clinicals from a seperate manufacturing plant of which has limited production. There are two plants involved but on further conversation with Idec it appears that it is the new facility that is currently being constructed for CE9.1 that will be the primary manufacturing facility of this product. They could not confirm to me that the existing facility will also be used for manufacturing upon approval. My appologies for any miscommunication. Nobody likes to see selling in any stock and Smithkline has been selling large chunks of stock for the past 2 years. Sometimes they sell before public release of clinical data and sometimes afterwards. In the past 2 years there has been no correlation of their selling to any clinical bad news and in hindsight they have always sold into good news or shortly thereafter. I attended last Octerber's American College of Rheumatology conference and listened to many presentations on RA of which the ACR highlighted at the conclusion of the conference 3 companies that had the most promising product and efficacy for RA. CE9.1 was one of the three and from the conversaton that I had with Smithkline they appeared to be equally as excited about the prospects of CE9.1 as Idec. An interesting fact is that Smithkline was selling stock at that point in time as well and during the prior year ACR meeting. I listened to most all of the competitors presentations and the more I listened the more excited I became on what Idec achieved compared to the competition. I do not recall seeing any info on ISIP on their RA product but will be interested to see what the future holds.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News